BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Rhea-AI Summary

BioNTech (NASDAQ: BNTX) has announced its second AI Day event, part of the company's Innovation Series, scheduled for October 1, 2025, at 9:00 AM EDT in London. The event will showcase BioNTech's artificial intelligence strategy and capabilities, particularly focusing on AI applications in their pipeline and internal processes.

The presentation will be accessible through a live webcast, with slides and recording available on BioNTech's Investor Relations website for one year following the event. This event marks a significant milestone in BioNTech's continued focus on AI development, following their acquisition of InstaDeep Ltd.

MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Wednesday, October 1, 2025, in London, United Kingdom. The event will provide an overview of BioNTech’s AI strategy and capabilities, and the application of AI in BioNTech’s pipeline and internal processes.

The live webcast of the event will be available via this link.

Participants may also access the slides and a recording of the event via the “Events & Presentations” page in the Investor Relations section of BioNTech’s website at www.BioNTech.com. The recording will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year thereafter.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit www.BioNTech.com.

CONTACTS

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

Media Relations
Jasmina Alatovic
Media@biontech.de

FAQ

When and where is BioNTech (BNTX) hosting its second AI Day in 2025?

BioNTech will host its second AI Day on October 1, 2025, at 9:00 AM EDT (3:00 PM CEST) in London, United Kingdom.

What topics will be covered at BioNTech's 2025 AI Day event?

The event will provide an overview of BioNTech's AI strategy and capabilities, along with their application in BioNTech's pipeline and internal processes.

How can investors access BioNTech's AI Day 2025 presentation?

Investors can access the event through a live webcast, with slides and recording available on BioNTech's Investor Relations website for one year after the event.

What is the significance of BioNTech's AI Day 2025?

This is BioNTech's second AI Day, showcasing the company's continued focus on artificial intelligence development through their AI company InstaDeep Ltd.